Reliability of Contrast CT and Positron Emission Tomography in Post-Surgical Colorectal Cancer and Its Association with Obesity

Safenaz Y. El Sherity1*, Shymaa A. Shalaby2, Nayera E. Hassan1, Sahar A. El-Masry1, Rokia A. El-Banna1

1Biological Anthropology Department, Medical Research Division, National Research Centre, Dokki, Giza, Egypt; 2Radiodiagnosis department, Faculty of Medicine, Helwan University, Cairo, Egypt

Abstract

BACKGROUND: Post-surgical recurrence of cancer colon occurs in one-third of patients within the first two years, so early detection is important. The assessment of the therapeutic response is important to change protocol strategy. Positron emission tomography/computed tomography PET/CT, a valuable tool gives both metabolic and anatomic information for whole-body regions. Obesity is an important risk factor for colorectal cancer.

AIM: To evaluate post-surgical and therapeutic colorectal cancer by PET/CT and study obesity association to its prognosis.

METHODS: This was a prospective study involved 93 patients with, post-surgical colorectal cancer examined by PET/CT, then follow up after 4-6 months.

RESULTS: There was a statistically significant difference between PET/CT and contrast CT. The specificity were (96.4%-100% & 92.3%-98.2%) for PET/CT and (84.2%-90.2% & 76.5%-85.4%) for contrast CT respectively. Post-therapeutic follow up showed: progressive course (24.5%), stationary course (26.4%), partial regression (28.3%) and complete regression course (20.8%). Obesity is a risk factor for progression with highly statistically significant to treatment response. Obese patients had a progressive or stationary course of the disease. Also, there was a highly statistically significant association between total abdominal fat & visceral abdominal fat areas with good response of treatment.

CONCLUSION: PET/CT is the most appropriate imaging technique to detect any recurrence or metastases in post-surgical colorectal cancer with high sensitivity and specificity comparing to CT. Obesity is a predictor risk factor for prognosis of the disease, as generally and abdominally (total & visceral fat) had an association with therapeutic response.

Introduction

Worldwide more than one million people get colorectal cancer yearly [1]. Also, it is the third most commonly diagnosed cancer in males and the second in females, with 1.8 million new cases and almost 861,000 deaths in 2018, according to GLOBOCAN database. The highest incidence rates are in Europe, North America, Australia, and New Zealand, while the lowest rates are in South-Central Asia and Africa [2]. Colorectal cancer is the 7th commonest cancer in Egypt; it represents 3.5% of male cancers and 3% of female cancers [3]. The estimated numbers of colon cancer patients were more than three thousand in 2015 [3].

Post-surgical recurrence of cancer colon occurs within the first two years. It can recur loco-regionaly or at distant sites [4]. In therapy, resection of one metastasis is associated with good survival rate while multifocal metastatic lesions give a less favourable prognosis [5]. Also, the assessment of the therapeutic response (chemo-radiotherapy) is important for change protocol strategy of ineffective and toxic chemotherapy [6]. So, early detection helps design the clinical therapeutic guidelines; secondary operation, radiotherapy or chemotherapy.

Serum carcinoembryonic antigen (CEA) and contrast computed tomography (CT) are conventional methods. As serum CEA levels are used for recurrence monitoring, with its high-level imaging modality will be necessary to localise the site of recurrence and metastases [7]. Regarding changes of
Patients and Methods

Design: A prospective study

Ethics: This study was approved by the research ethics committee, faculty of medicine, Helwan University (FMHU 1-2019) and informed written consent were signed by each patient.

Participants: Ninety-four Egyptian’s patients with post-surgical cancer colon, examined for follow up after 4-6 months by PET/CT, both genders were included in this study (55 males and 39 females); their ages were ranged from 38 to 75 years. They were referred from clinical oncology and surgery departments due to elevated CEA or follow up to assess the effect of treatment. The inclusion criteria: pathologically proven colorectal carcinoma and underwent appropriate therapy for 4-6 months. Exclusion criteria included those who had a bad general condition, impaired renal function, allergy to intravenous contrast material and a blood glucose level > 200 mg/dl at the time of the study.

The duration of the study: January 2019- June 2019.

The mid: allow low carbohydrate diet to prevent recurrence of treatment. The inclusion criteria: complete history was calculated using PASS effect of treatment. The inclusion criteria: a pathologically proven colorectal carcinoma and complete blood count, blood coagulation, liver and renal function tests, ECG, chest X-ray and chest CT. The exclusion criteria included those who underwent appropriate therapy for 4 months and pathologically proven colorectal carcinoma.

Several studies reported that obesity is an important risk factor for colorectal cancer [10], [11], [12], [13], while Scarpa et al., showed the role of obesity in postoperative recurrence and multifocal disease [14].

The aims of this study; to evaluate post-surgical and therapeutic colorectal cancer by PET/CT for proper management, also predict the effect of obesity as a risk factor in prognosis among a sample of Egyptian patients.

Sample size estimation

The sample size was calculated using PASS 11 (USA), regarding the proportional of PET/CT sensitivity at the previous study; 90 subjects were adequate with power 90.0%, α = 0.05, and B = 0.1

Methods

Patient preparation: allow low carbohydrate and high protein diets with liquids (24 hours before), then fasting 6 hours before the examination.

The day of examination: complete history was taken and indication (High tumour marker CEA and previous PET/CT scan for follow up), then measurements were taken before starting the examination: Fasting blood sugar, body height and weight (using a Seca scale balance and anthropometer with light clothes and no shoes, the measure was taken to nearest 0.1 cm and 0.01 kg respectively) [15]. The Body mass index (BMI) was calculated as; the weight (kg)/ height (m²) and classified into; (18.5 ≥ normal weight < 25), (≥ 25 overweight < 30) and obese (≥ 30) [16].

Examinations: Intravenous injection of 5 – 10 mCi as an average dose of 18F-FDG (0.1 mCi/Kg) one hour before starting the scan. Each patient was examined by PET/CT using Phillips Ingenuity TF, 128 slice machines (Cleveland, OH, USA) as the following: A low-dose non-contrast CT for attenuation correction followed by PET scan from the skull to the mid-thigh, then a diagnostic post-contrast CT using nonionic contrast medium. Those PET images were assessed by both visually & semi-quantitatively for the regions with pathologic tracer accumulation using maximum standardized uptake value (SUV max); loco-regional lesion (recurrent) was identified by presence of metabolically active tumour tissue with high FDG accumulation and correlated this activity to its anatomical site in the combined PET/CT images, the lymph nodes and distant metastases (lung, liver, bone, brain, and others) were evaluated as well. The comparison between the recent scan and the previous one in follow up cases was made to evaluate the response of treatment (Fig. 1).

The assessment of therapeutic response evaluated by PET/CT according to RECIST criteria [17]:

- Complete response (CR): The disappearance of FDG uptake at the target tumour lesion.no new FDG avid lesion.

- Partial response (PR): reduction at least a 30% in target measurable tumour FDG uptake, taking the baseline lesion as a reference.

- Progressive disease (PD): at least a 25% increase in tumour SUVmax peak uptake, taking a reference the baseline lesion from starting of treatment or an appearance of a new lesion or more.

- Stationary disease (SD): no sufficient
changes, almost same as reference baseline lesion from starting of treatment; less than 25% increase (not PD) and 30% decrease (not PR). No new lesion.

Regarding abdominal fat assessment, no extra-scan was required, the analysis was processed by special software at an advanced workstation (AW Volumeshare2- version 4.4 Software), assessed total, visceral and subcutaneous abdominal fat compartments at the L4-L5 level by drawing then a calculation of area was done.

**Statistical Analysis**

SPSS version 22 software was used to analyse the data; mean ± standard deviations (SD) for parametric data, numbers (percentage) for the frequency distribution of non-parametric data, crosstabs for sensitivity and specificity, Chi-square, Pearson’s correlation test, and odds ratio. A significance was set at P = 0.05

**Results**

This study included 94 patients: 55 male (58.5%) and 39 female (41.5%), their age ranged from 38 to 75 years (mean ± SD: 58.3 ± 4.1 years), weight; 61-109 kg (90.9 ± 5.8 kg), height; 153-169 cm (162.8 ± 3.7 cm), BMI; 22.6-39.8 kg/m2 (34.4 ± 5.4 kg/m2) and fasting blood sugar; 70-197 mg/dl (101.2 ± 2.4 mg/dl). Regarding BMI; 31 (33%) were of normal weight (20 males and 11 females), 12 (12.8%) were overweight (7 males and 5 females) and 51 (54.3%) were obese (28 males and 23 females), then classified into two groups; the first one included normal weight patients and the second one included both; overweight & obese to involve 63 patients (67%)(35 males and 28 females).

Regarding indications; 41 patients underwent PET-CT post-surgical, while 53 patients follow up post-therapeutic (chemo and radiotherapy) to assess the response of treatment, as well, 62 patients (66%) had elevated tumour marker CEA, and 32 had a negative marker (34%). The CEA was (0.9-116 ng/ml).

The frequency distribution of local recurrence lesions and metastatic deposits detected by contrast CT and PET/CT imaging for a total of 94 patients (Table 1), revealed; lymph nodes metastasis were the most frequent site (36.2% and 46.8%) for CT and PET/CT respectively followed by local recurrence & hepatic deposits (25.5%) by CT, while local recurrence represents (34%) by PET/CT then peritoneal deposits (18.1% and 28.7%), pulmonary deposits (14.9% and 17%) and osseous deposits (11.7% and 23.4%) by CT and PET/CT respectively. Although PET/CT gives additional information about active tumour cell by measuring its avidity to 18F-FDG uptake and measuring the maximum standardised uptake values (SUVmax). Its ranges were; 9-29.4 (mean 17.2 ± 5.4 SD) for local recurrence, 4.5-29.7 (mean 13.3 ± 6.9 SD) for LN metastasis, 5.7-23 (mean 10.7 ± 5.2SD) for hepatic deposits, 7.7-15.3 (mean 11.9 ± 2.5SD) for peritoneal deposits, 7.7-15.3 (mean 10.8 ± 6.1SD) for pulmonary deposits and 4.5-11.8 (mean 9.1 ± 1.7SD) for osseous deposits.

There were statistically significant differences between contrast CT and PET/CT (P = 0.000); 8 cases of local recurrence were missed by CT and detected by PET/CT, 10 cases of metastatic LNs and peritoneal deposits detected only PET/CT may be due smaller in size to localize by CT, as well extra 11 osseous lesions were detected by PET/CT (bone marrow affection) compared to CT, while two pulmonary nodules couldn’t be detected by CT as it surrounded by consolidation area and pleural effusion.

Then, the sensitivity and the specificity of PET/CT was done related to elevated tumour markers, measuring (96.4%-100% & 92.3%-98.2% respectively) compared to contrast CT (84.2%-90.2% & 76.5%-85.4% respectively), the positive and negative predictive values were 94% and 84% for PET/CT, and 81% and 76.3% for CT.

Regarding obesity, all patients were classified according to BMI categories; normal weight and (overweight & obese) with PET/CT findings to detect frequency of local recurrence and metastatic deposits on each group (Table 2), There was an insignificantly statistical association between obesity and PET/CT findings (no significant differences regarding sex), however, the most frequent local recurrence and metastatic deposits were detected at obese patients (71.9%-81.2%).

**Table 1: Frequency distribution of local recurrence and metastatic lesions detected by Contrast CT and PET/CT**

|                      | Contrast CT | PET/CT | p-value |
|----------------------|-------------|--------|---------|
| Local Recurrence     | 24 (25.5%)  | 32 (34%) | 0.000   |
| LN Metastasis        | 34 (36.2%)  | 44 (46.8%) | 0.000   |
| Peritoneal Deposits  | 17 (18.1%)  | 27 (28.7%) | 0.000   |
| Pulmonary Deposits   | 14 (14.9%)  | 16 (17%)  | 0.000   |
| Hepatic Deposits     | 24 (25.5%)  | 24 (25.5%) | 0.000   |
| Osseous Deposits     | 11 (11.7%)  | 22 (23.4%) | 0.000   |

**Table 2: Comparison between BMI categories (normal weight and overweight & obese) with PET/CT findings**

|                      | Normal Weight | Overweight & Obese | p-value |
|----------------------|---------------|---------------------|---------|
| Local Recurrence     | 9 (28.1%)     | 23 (71.9%)          | 0.312   |
| LN Metastasis        | 12 (37.3%)    | 32 (70.2%)          | 0.074   |
| Peritoneal Deposits  | 9 (33.3%)     | 18 (66.7%)          | 0.865   |
| Pulmonary Deposits   | 3 (18.8%)     | 13 (81.2%)          | 0.510   |
| Hepatic Deposits     | 5 (20.8%)     | 19 (79.2%)          | 0.314   |
| Osseous Deposits     | 6 (27.3%)     | 16 (72.7%)          | 0.786   |

Then frequency distribution between obesity and response of treatment (post-therapeutic follow up) was done (Table 3). Fifty-three patients were classified; normal weight and (overweight and obese),
The assessment depends on the avidity of the lesion to 18 F-FDG uptakes, quantitative analysis by measuring (SUVmax) value and compared with the previously PET/CT scan from 4-6 months. Thirteen patients (24.5%) had a progressive course of the disease, all were obese, while good response of treatment was recorded at 40 patients (75.5%) as the following: stationary course (26.4%) (57.1% of them were obese), partial regression (28.3%) (60.0% of them were within normal weight) and complete regression course (20.8%) (54.5% of them were within normal weight).

Table 3: Frequency distribution between obesity and response of treatment (Post-therapeutic follow up)

| Progression | Total No. | Frequency |
|-------------|-----------|-----------|
| Progressive | 13 (24.5%)| 6 (42.9%) |
| Good response to treatment: | 40 | 20 |
| Stationary | 14 (26.4%)| 6 (42.9%) |
| Partial Regression | 15 (28.3%)| 9 (60.0%) |
| Complete Regression | 11 (20.8%)| 6 (45.5%) |

The odds ratio was done to know the effect of obesity as a risk factor on the progression of cancer colon (Table 4). There was highly statistical significance with a response of treatment (p = 0.001, odd value > 2 and CI = 1.46-2.72), also hepatic and pulmonary deposits had high precision by odd value and 95% confidence interval (CI), followed by LN metastasis and local recurrence, while peritoneal and osseous deposits had a low association with obesity.

Table 4: Odds ratio to predict if obesity a risk factor for the progression of the cancer colon

| Response of treatment | Odd Value | 95% Confidence Interval | P-Value |
|-----------------------|-----------|------------------------|---------|
| Local Recurrence | 1.4 | 0.555-3.56 | 0.472 |
| LN Metastasis | 1.5 | 0.822-2.481 | 0.061** |
| Peritoneal Deposits | 0.9 | 0.382-2.366 | 0.851 |
| Pulmonary Deposits | 2.3 | 0.601-8.755 | 0.215 |
| Osseous Deposits | 2.1 | 0.703-6.341 | 0.137 |
| ** Highly Significant at P ≤ 0.001. |

For more specification of obesity, the abdominal obesity assessed by CT and measured; total abdominal fat, subcutaneous fat and visceral abdominal fat areas (cm²), their range (100.4-998.7 cm²), (80-789.6 cm²) and (18.27-267 cm²) respectively. Then a comparison between abdominal obesity and response of treatment (post-therapeutic follow up) regarding sex was made (Table 5).

Table 5: Comparison between abdominal obesity and the response of treatment (Post-therapeutic follow up) regarding sex

| Sex | Progressive course | Good response to treatment |
|-----|--------------------|---------------------------|
|     | Mean ± SD | Mean ± SD | p-value |
| Total abdominal fat (cm²) | Male | 683.72 ± 60.5 | 618.20 ± 25.5 | 0.006 |
| Subcutaneous | Female | 834.74 ±102 | 463.04 ± 24.9 | 0.054 |
| Visceral abdominal fat (cm²) | Male | 412.11 ±36.0 | 349.16 ± 44.8 | 0.203 |
| Females | 203.54 ± 32.5 | 334.70 ± 45.5 | 0.370 |
| Obese | Male | 217.50 ± 38.3 | 138.02 ± 35.7 | 0.000 |
| Females | 229.50 ± 53.5 | 100.75 ± 42.5 | 0.004 |

It was revealed that; 31 males and 9 females had a good response of treatment, while 11 males and 2 females had progressive course after treatment. There was a highly statistically significant difference between total abdominal fat & visceral abdominal fat areas with good response of treatment at both sexes (P ≤ 0.001). However, no statistically significant difference was detected with a subcutaneous fat area.

Figure 2: A 72-years old obese male patient, referred after resection of the recto-sigmoid mass and chemo-radiotherapy for follow up. Axial PET/CT images for two examinations; the first (a-d images) and the second examination (e, f, g, h images) after 4 months of treatment for comparison revealed; (a and e) progression of hyper-metabolic peri-rectal soft tissue nodule achieving 13.38 SUVmax (6.79 SUVmax previously) (green arrow), while another lesion (yellow arrow image a) can't be detected in newly one (b and f) a small active hypermetabolic lesion (recurrant) is seen at the distal sigmoid colon, achieving 9.86 SUVmax (red arrow image f) (c and g) Newly developed a small hyper-metabolic peritoneal nodule is noted achieving 5.44 SUVmax (yellow arrow image g) (d and h). Metabolically and morphologically progression of porta-hepatis lymph node, achieves 20.37 SUVmax (red arrow image l) (c and g) and newly developed active right hepatic lobe focal lesion is seen (segment VI) achieves 8.42 SUVmax (red arrow)

Discussion

The most serious problem of colorectal cancer is a recurrence, as it represents around 10% -
50% within 5 years after the surgery in the form of local or distant. So, the key to diminishing postoperative recurrence is early detection for fast proper management to improve the survive [9].

Postoperative monitoring was done by CEA serum level when elevated suspected of recurrence and imaging modality is necessary to detect any metastasis [18]. Contrast CT could be detected only sizable morphological changes, however, its inability to discriminate inflammatory lesions from recurrence or metastases [7], while 

$^{18}$F-FDG PET/CT shows early metabolic changes to detect any recurrence or metastases for choosing an adequate plan of therapy [8].

Several studies and meta-analysis studies reported a strong positive association between obesity and colorectal cancer. It estimated 30%-50% of new diagnosed colorectal cancer cases [14, 19, 20, 21]. Also, obesity had an effective role in recurrence and prognosis of treatment, as those patients were obese had a higher incidence of recurrence than those had normal or over-weight [13]. Obesity was assessed by BMI, while abdominal obesity was evaluated by CT scan cut at L4 – L5 level [22].

In this Egyptian study, the first purpose was evaluating the role of PET/CT in post-surgical cancer colon comparing to contrast CT, revealed that sensitivity of CT was 84.2%-90.2% and for PET/CT was 96.4%-100%, whereas the specificity of CT was 76.5%-85.4% and for PET/CT was 92.3%-98.2%. These were in agreement with the previous studies; that had approved PET/CT was the technique of choice for postoperative assessment of colorectal cancer to detect recurrence with sensitivity (93%-100%) and specificity (74%-96%) [5], [6]. While, Stuckle et al., reported the sensitivity of CT was 38% – 82% in the detection of the recurrence [23].

In this study, more lesions were detected by PET/CT compared to CT, in spite of the same number of hepatic and almost pulmonary deposits were found in both imaging modalities. This, in agreement with Choi et al. as well had added abdominal LN [24].

Additionally, lymph nodes were the most frequent site of recurrence (46.8%) in the current study by PET/CT, followed by local recurrence (34%), peritoneal deposits (28.7%), hepatic deposits (25.5%), osseous deposits (23.4%) and pulmonary deposits (17%).

Many studies reported that lymph nodes were the most frequent site of recurrence [25], [26]. However, Owen et al. found the liver metastasis was the most frequent site (50%) [27] and Chiewvit et al., reported, the pulmonary metastatic was the second site [28]. Regarding osseous lesions more lesions detected by PET/CT due to bone marrow affection, this is by Bar-Shalom et al., study, as no corresponding CT findings (osteolytic lesions or destruction of bone) at the same detected site by PET/CT [29].

The second purpose of this research was to assess the association between obesity and colorectal cancer recurrence. Our findings revealed that the most frequent local recurrence and metastatic deposits were detected at obese patients (71.9%-81.2%). Several studies concluded the association between obesity and colorectal cancer, as well obese patients had higher recurrence and mortality rates than normal and overweight patients [14, 30, 31, 32], the incidence of obese patients had colorectal cancer was 11.9%-40% in Italian study [33]. The commonest mechanism could be clarified this association; effect of high leptin level at obese persons, which induce pre-neoplastic epithelial cells of the colon [34].

Our results regarding post-therapeutic follow up and prognosis of the disease showed that obesity was highly statistically significant with response of treatment ($p = 0.001$, odds value > 2 and CI = 1.46-2.72), as obese patients had progressive or stationary course (100% and 57.1% respectively), while normal-weight patients had partial and complete regression course (60.0% and 54.5% respectively). Also, there was a highly statistically significant difference between total abdominal fat & visceral abdominal fat areas with good response of treatment at both sexes. This agreement with Jochem and Leitzmann, they found general obesity (BMI) and abdominal obesity had increased risk of colorectal cancer in both sexes [32]. Increased visceral fat area, not subcutaneous or total body fat, was established as the metabolic risk factors for colon cancer, those patients had 1.5 times of the visceral fat area compared to patients without that [35].

Finally, this research has an important recommendation to add at the therapeutic strategy plan of colorectal cancer; reduce body weight and preserve it within normal to improve the response of the treatment.

In conclusion, positron Emission Tomography (PET/CT) is the most appropriate imaging technique to detect any recurrence or metastases in post-surgical& therapeutic follow up colorectal cancer patients with high sensitivity and specificity compared to computed tomography (CT). General obesity is a predictor risk factor for prognosis of the disease, although abdominal obesity (total & visceral fat) had an association with a therapeutic response; as the progressive and stationary courses of the disease were noticed at obese patients with high visceral and total abdominal fat.

Acknowledgements

Authors are grateful to all participated in this study, patients and staff members of the Misr
radiology centre (MRC), Cairo, Egypt.

Author Contribution

Safanaz Y. El Sherity (corresponding author): designed the study, statistical analysis, interpretation of the data and wrote the manuscript. Shyamma A. Shalaby: collected the data and shared in manuscript writing. Nayera E. Hassan, Sahar A. El-Masry, and Rokia A. El-Banna: gave conceptual advice and manipulation of the data. All authors share in references collection, drafting the article and approval the final version.

References

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013; 63:11-30. https://doi.org/10.3322/caac.21166 PMid:23335087

2. Fitzmaurice C, Allen C, Barber RM, Barregard L, Bhutta ZA, Brenner H, Dicker DJ, Chimed-Orchir O, Dandona R, Dandona L, Fleming T. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: a systematic analysis for the global burden of disease study. JAMA oncology. 2017; 3(4):524-48. https://doi.org/10.1001/jamaoncol.2016.5688 PMid:27918777 PMCid:PMC56103527

3. Metwally I, Shetawy M, Elalfy A, Abouzid A, Saleh S and Hamdy M. Epidemiology and survival of colon cancer among Egyptians: a retrospective study. J coloproctol (rioj). 2018; 38(1):24. https://doi.org/10.1016/j.jcol.2017.09.418

4. Zafar H, Mahmoud N, Mira N, et al: Resected colorectal cancer among Medicare beneficiaries: Adoption of FDG PET. Radiology. 2010; 254:501-508. https://doi.org/10.1148/radiol.2541090484 PMid:20903522

5. Fehr M, Müller J, Knitel M, Fornaro J, Horber D, Koeberle D. Early Postoperative FDG PET/CT Imaging Results in a Relevant Upstaging in the pN2 Subgroup of Stage III Colorectal Cancer Patients. Clinical colorectal cancer. 2017; 16(4):343-8. https://doi.org/10.1016/j.clcc.2017.03.007 PMid:28412138

6. Sobhani I, Itti E, Luciani A, Baumgaertner I, Layese R, André T, Dureuxs M, Gornet JM, Goujon G, Apricio T, Taeieb J. Colorectal cancer (CRC) monitoring by 6-monthly 18FDG PET/CT: an open-label multicentre randomised trial. Annals of Oncology. 2018; 29(4):931-7. https://doi.org/10.1093/annonc/mdy031 PMid:29365058 PMCid:PMC5913635

7. Chen L, Tong J, Song H, Zhu H, Wang Y. 18F-DG PET/CT in detection of recurrence and metastasis of colorectal cancer. World J Gastroenterol. 2007; 13(37):5025-5029. https://doi.org/10.3748/wjg.v13.i37.5025 PMid:17854148 PMCid:PMC443629

8. Chan K, Welch S, Walker-Diks C, Raifu A. Evidence-based guideline recommendations on the use of Positron Emission Tomography Imaging in colorectal cancer. Clinical Oncology. 2012; 24:232-249. https://doi.org/10.1016/j.clon.2011.11.008 PMid:22192782

9. Bailey C, Hu C, You Y, Kaur H, Ernst R, Chang G. Variation in Positron Emission Tomography Use After Colon Cancer Resection, journal of oncology practice. 2015; 11(3):363-372. https://doi.org/10.1200/JOP.2014.010933 PMid:25852143 PMCid:PMC4438115

10. Renehan A, Tyson M, Egger M, Heller RF, Zwahlen M. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet. 2008; 371:569-578. https://doi.org/10.1016/S0140-6736(08)60269-X

11. Moghaddam AA, Woodward M. Huxley R. Obesity and risk of colorectal cancer: a meta-analysis of 31 studies with 70,000 events. Cancer Epidemiology and Prevention Biomarkers. 2007; 16(12):2533-47. https://doi.org/10.1158/1055-9965.EPI-07-0708 PMid:18086756

12. Larsson S, Wolk A. Obesity and colon and rectal cancer risk: a meta-analysis of prospective studies. Am J Clin Nutr. 2007; 86:556-565. https://doi.org/10.1093/ajcn/86.3.556 PMid:17823417

13. Ma Y, Yang Y, Wang F, et al. Obesity and risk of colorectal cancer: a systematic review of prospective studies. PLoS One. 2013; 8(1):e53916. https://doi.org/10.1371/journal.pone.0053916 PMid:23349764 PMCid:PMC3547959

14. Scarpà M, Ruffolo C, Erro F, Fiorato A, Basato S, Pozza A, Canal F, Massani M, Cavallin F, Antoniutti M, Nicolò B, Castoro C. Obesity is a Risk Factor for Multifocal Disease and Recurrence after Colorectal Cancer Surgery: A Case-Control Study. Anticancer Research. 2014; 34:5735-5742.

15. Hiernaux J, Tanner J. Growth and physical studies. In J. S. Weiner, S. A. Louine (Eds.), Human Biology: A guide to field methods. London: IBP; Oxford, UK: Blackwell Scientific Publications, 1969.

16. Lauby-Secrétan C, Scoccianti C, Loomis D, Grosse Y, Bianchini F, Straif K. Body fatness and cancer-viewpoint of the IARC Working Group. N Engl J Med. 2016; 75(8):794-8. https://doi.org/10.1056/NEJMsr1606602 PMid:27557308

17. Monteil T, Mahmoud N, Lebon S, Roudaut P, El badaoui A, Verbeke S, Venat-bouvet I, Martin J, Le brun-ly V, Lavau-denes S, Maubon A, Bouillet P, Pouquet M, Vandroux J, Tubiana-mathieu N. Chemotherapy response evaluation in metastatic colorectal cancer with FDG PET/CT and CT scans. Anticancer research, 2009; 29:2563-2568.

18. Nakamoto Y, Sakamoto S, Okada T, Senda M, Higashi T, Saga T, et al. Clinical value of manual fusion of PET and CT images in patients with suspected recurrent colorectal cancer. AJR Am J Roentgenol. 2007; 188:257-67. https://doi.org/10.2214/AJR.05.0708 PMid:17179375

19. Doubeni C, Laiyemo A, Major J, et al. Socioeconomic status and the risk of colorectal cancer: an analysis of more than a half million adults in the National Institutes of Health-AARP Diet and Health Study. Cancer, 2012; 118:3636. https://doi.org/10.1002/cncr.26677 PMid:22898918 PMCid:PMC3422782

20. Doubeni C, Major J, Laiyemo A, et al. Contribution of behavioral risk factors and obesity to socioeconomic differences in colorectal cancer incidence. J Natl Cancer Inst. 2012; 104:1353. https://doi.org/10.1093/jnci/djs346 PMid:22952311 PMCid:PMC3529596

21. Karahalios A, English, Simpson J. Weight change and risk of colorectal cancer: a systematic review and meta-analysis. Am J Epidemiol. 2015; 181:832. https://doi.org/10.1093/aje/kwu357 PMid:25888582

22. El-Serag HB, Hashmi A, Garcia J, Richardson P, Alsaaraj A, Fitzgerald S, Vela M, Shafi Y, Abraham NS, Velez M, Cole R. Visceral abdominal obesity measured by CT scan is associated with an increased risk of Barrett's oesophagus: a case-control study. Gut. 2014; 63(2):220-9. https://doi.org/10.1136/gutjnl-2012-304189 PMid:23408348 PMCid:PMC3976427

23. Stückle CA, Haegelke KF, Jendreck M, Kickuth R, Schneider O, Hollibach G, Liermann D. Improvements in detection of rectal cancer recurrence by multiplanar reconstruction. Der Radiologue. 2005; 45(10):930-4. https://doi.org/10.1007/s00117-003-0950-3 PMid:16252127

https://www.idpress.eu/jmjs/index
24. Choi E, Yoo L, Han E, Oo J, Kim S, Chung S. Value of surveillance F-18 FDG PET/CT in colorectal cancer: comparison with conventional imaging studies. J Nucl Med. 2010; 51(2 Suppl):1208.

25. Ong M, Schofield J. Assessment of lymph node involvement in colorectal cancer. World J Gastrointest Surg. 2016; 8(3):179-192. https://doi.org/10.4240/wjgs.v8.i3.179 PMid:27022445 PMCid:PMC4807319

26. Littlechild J, Junejo M, Simons A, Curran F, Subar D. Emergency resection surgery for colorectal cancer: Patterns of recurrent disease and survival. World J Gastrointest Pathophysiol. 2018; 9(1):1-36. https://doi.org/10.4291/wjpp.v9.i1.8 PMid:29487762 PMCid:PMC5823701

27. O’Connor OJ, McDermott S, Slattery J, Sahani D, Blake MA. The use of PET-CT in the assessment of patients with colorectal carcinoma. International journal of surgical oncology. 2011; 2011. https://doi.org/10.1155/2011/846512 PMid:22312527 PMCid:PMC3263658

28. Chiewvit S, Jiranantanakom T, Apisarnthanarak P, Kanchanaapiboon P, Hannanthawiwat C, Ubolnuch K, et al. Detection of recurrent colorectal cancer by 18F-FDG PET/CT comparison with contrast enhanced CT scan. J Med Assoc Thai. 2013; 96(6):703-8.

29. Bar-Shalom R, Yefremov N, Guralnik L. Clinical performance of PET/CT in evaluation of cancer: additional value for diagnostic imaging and patient management. J Nucl Med. 2003; 44:1200-1209.

30. Omata F, Deshpande G, Ohde S, Mine T, Fukui T. The association between obesity and colorectal adenoma: systematic review and meta-analysis. Scand J Gastroenterol. 2013; 48(2):136-46. https://doi.org/10.3109/00365521.2012.737364 PMid:23130986

31. Yun KE, Chang Y, Jung HS, Kim CW, Kwon MJ, Park SK, Sung E, Shin H, Park HS, Ryu S. Impact of body mass index on the risk of colorectal adenoma in a metabolically healthy population. Cancer research. 2013; 73(13):4020-7. https://doi.org/10.1158/0008-5472.CAN-12-3477 PMid:23687341 PMCid:PMC4807319

32. Jochem C, Leitzmann M. Obesity and Colorectal Cancer. Recent Results Cancer Res. 2016; 208:17-41. https://doi.org/10.1007/978-3-319-42542-9_2 PMid:27909900 PMCid:PMC5263658

33. Sistema statistico nazionale - istituto nazionale di statistica: Indagine multiscopo annuale sulle famiglie “Aspetti della vita quotidiana” Anno 2009. ISTAT, 2010.

34. Birmingham J, Busik J, Hansen-Smith F, Fenton J. Novel mechanism for obesity-induced colon cancer progression. Carcinogenesis. 2009; 30(4):690-697. https://doi.org/10.1093/carcin/bgp041 PMid:19221001 PMCid:PMC2664456

35. Frezza E, Wachtel M and Chiriva-Internati M. Influence of obesity on the risk of developing colon cancer. Recent advances in clinical practice. Gut. 2008; 55:285-291. https://doi.org/10.1136/gut.2005.073163 PMid:16239255 PMCid:PMC189617